New shot aims to tame hepatitis b virus in long-term patients
NCT ID NCT05961098
First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 20 times
Summary
This study tested a new medicine, RBD1016, in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the drug is safe and can lower a key virus marker (HBsAg) in the blood. Results will help decide if larger studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Consultants AB
Uppsala, Uppsala County, 752 37, Sweden
-
Karolinska University Hospital
Stockholm, Stockholm County, 141 86, Sweden
-
Prince of Wales Hospital
Hong Kong, China
-
Queen Mary Hospital
Hong Kong, China
Conditions
Explore the condition pages connected to this study.